Robert LeBoyer

Stock Analyst at Noble Capital Markets

(1.53)
# 3,526
Out of 5,124 analysts
18
Total ratings
31.25%
Success rate
0.9%
Average return

Stocks Rated by Robert LeBoyer

Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $15.62
Upside: +348.14%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $4.55
Upside: +185.71%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6$10
Current: $0.17
Upside: +5,747.95%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $5.77
Upside: +939.86%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $6.78
Upside: +784.96%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $1.51
Upside: +562.25%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.53
Upside: +815.03%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.67
Upside: +379.04%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.51
Upside: +23,323.78%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $13.47
Upside: -
Initiates: Buy
Price Target: $12
Current: $3.56
Upside: +237.08%
Initiates: Buy
Price Target: $9,900,000
Current: $5.25
Upside: +188,571,328.57%
Downgrades: Neutral
Price Target: n/a
Current: $39.99
Upside: -
Initiates: Buy
Price Target: $15
Current: $3.23
Upside: +364.40%